Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.480 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript ↗

September 17, 2026

Lacutamab advances toward accelerated approval as ADC pipeline expands.

Via The Motley Fool

Topics Earnings

Innate Pharma Q2 Earnings Call Highlights ↗

September 17, 2026

Innate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and...

Via MarketBeat

Topics Earnings

Innate Pharma Reports First Half 2026 Business Update and Financial Results

September 17, 2026

From Innate Pharma SA

Via Business Wire

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

September 16, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

September 10, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 02, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Secures €30M, Extends Cash Runway Into 2028 ↗

August 14, 2026

Innate Pharma (NASDAQ:IPHA) said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs...

Via MarketBeat

Innate Pharma Announces Conference Call and Webcast

August 14, 2026

From Innate Pharma SA

Via Business Wire

Unusual volume stocks are being observed in Wednesday's session. ↗

August 12, 2026

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

August 11, 2026

Via Chartmill

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

August 10, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

August 10, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

July 23, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

July 21, 2026

From Innate Pharma SA

Via Business Wire

Outcome of Innate Pharma’s 2026 Annual General Meeting

May 22, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to participate in the Jefferies Global Healthcare Conference

May 19, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Q1 Earnings Call Highlights ↗

May 13, 2026

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502...

Via MarketBeat

Topics Earnings

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

May 13, 2026

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

May 12, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

May 06, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in the D. Boral Capital Global Conference

April 23, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

April 17, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026

April 13, 2026

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

April 13, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event

April 08, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma to Participate in the Kempen Life Sciences Conference

April 03, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report

April 02, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

March 26, 2026

From Innate Pharma SA

Via Business Wire

Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results

March 19, 2026

From Innate Pharma SA

Via Business Wire

Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

February 19, 2026

From Innate Pharma SA

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.